ABio materials Eyes Leadership in Global Medical Skin Booster Market w…
페이지 정보
작성일 24-09-06
본문
Leading the charge in the skincare revolution, ABio materials is leveraging plant-derived exosome technology to establish itself as a frontrunner in the global medical skin booster market.
As the exosome-based skincare market continues to expand, this cutting-edge biotech company is poised to make significant strides on the international stage.
Exosomes are nano-sized extracellular vesicles, ranging from 30 to 150 nanometers, encapsulated by a lipid bilayer. These vesicles carry bioactive molecules such as proteins, lipids, and nucleic acid such as DNA and miRNA, which are transferred from one cell to another, facilitating intercellular communication and physiological processes. This unique ability aligns perfectly with the goals of the cosmetic and medical device industries, particularly in skin regeneration and rejuvenation.
Exosomes can be sourced from various origins, including plant-derived, mammalian-derived, and bacterial-derived sources, each reflecting the condition of their respective cells. While mammalian-derived exosomes, especially those from human cells, have seen widespread commercial success, plant-derived exosomes are now emerging as a promising alternative.
Plant-derived exosomes offer several distinct advantages over their human-derived counterparts. These include enhanced biocompatibility, lower production costs, and a broader spectrum of therapeutic properties due to the vast diversity of plant species. Unlike human-derived exosomes, which are limited by their origin, plant-derived exosomes can be sourced from countless species, each offering unique benefits—a prospect that excites industry stakeholders.
The current methodologies for exosome isolation, such as tangential flow filtration (TFF) and ultracentrifugation, often involve complex processes that can result in contamination with impurities. Recognizing these limitations, ABio materials has developed an innovative technology known as ExoTraction®. Unlike conventional methods that rely on callus culture, ExoTraction® Isolates and purifies exosomes directly from the plant material itself, bypassing the need for chemical treatments. This eco-friendly approach targets exosomes specifically, ensuring a high-purity extraction without the use of physical filtration or centrifugation, representing a significant technological advancement.
ABio materials' ExoTraction® technology has led to the development of 26 patents and over 40 plant-derived exosome formulations, positioning the company as a leader in the field. Their groundbreaking work has attracted attention from major global cosmetic companies, including Amorepacific, eager to collaborate on future innovations.
CEO Park Si-jun emphasized the revolutionary potential of plant-derived exosomes, stating, "While traditional plant extracts focus on the secondary metabolites produced by plant cells, plant-derived exosomes offer a more comprehensive approach to improving skin health by targeting the entire cellular structure." He further noted, "Plant exosomes help maintain the skin's regenerative cycle at levels typically seen in individuals in their twenties, making them a crucial player in the next generation of medical skin boosters, potentially surpassing the effects of Botox and fillers."
Beyond product development, ABio materials is also actively pursuing strategic partnerships and collaborations with leading domestic and international companies. These alliances aim to explore new applications of exosome technology, further solidifying the company's influence in the global biotech market.
As ABio materials continues to expand its presence on the global stage, its commitment to leveraging innovative biotechnology for health and beauty remains steadfast. With the exosome beauty market experiencing rapid growth worldwide, all eyes are on ABio materials as it charts the future of skincare with its pioneering exosome technology.
Source : SEN Money(https://www.senmoney.co.kr)
관련링크
- 다음글에이바이오머티리얼즈, 식물 엑소좀 기술로 세계 메디컬 스킨부스터 시장의 리더를 꿈꾸다 24.09.06